Afatinib Versus Erlotinib in Advanced SCC of the Lung

June 24, 2015
Shirish Gadgeel, MD

Shirish Gadgeel, MD, Barbara Ann Karmanos Cancer Institute, discusses a phase III study examining afatinib versus erlotinib as a second-line treatment of patients with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy.